patients from various data bases that are becoming available. Unfortunately, we are less able to define how and why therapeutic decisions are made and with what results.
The use of oral hypoglycemic agents in the management of hyperglycemia in patients with non-insulin-dependent diabetes mellitus (NIDDM) dates back to the early 1950s. It is indeed remarkable that 31 years after their approval by the Food and Drug Administration almost as many questions remain unanswered about their use as existed then (1, 2) . Very little data from well-controlled, properly designed clinical studies are available to define the efficacy of oral hypoglycemic agents in sustaining long-term (>5 years) near normoglycemic regulation or in preventing or retarding the development of chronic complications (1, 2) . Some concerns about their potential cardiovascular toxicity continue to linger (3) . The relative advantages and disadvantages of oral hypoglycemic agent therapy versus insulin therapy continue to be argued (4) (5) (6) (7) (8) .
The article "Trends in Use of Oral Hypoglycemic Agents: 1964-1986" appearing in this issue (p. 558) presents data on the pattern of oral hypoglycemic agent therapy in the United States. The data have no bearing on the questions of efficacy or side effects of oral hypoglycemic agents in general or individual drugs specifically but relate only to patterns of medical practice. Several conclusions can be derived from the data. The impact of the University Group Diabetes Program (UGDP) findings that were published initially in 1970 (9) and raised concerns about the safety and efficacy of oral hypoglycemic agents had little or no discernable effect on oral hypoglycemic agent usage until 1975. The nadir in their use occurred in 1979. Following the publication of the revised policy statement of the American Diabetes Association on oral hypoglycemic agents in 1979 (10), the use of these agents began to increase and this trend has continued to the present. The authors estimate that in 1986, 35.7% of diagnosed diabetic patients were treated with oral hypoglycemic sulfonylureas compared to 29.5% in 1982. This represents an increase in usage of 21 % in 5 years. Thus the negative impact of the UGDP findings took many years to appear whereas the positive impact of the revised policy statement occurred much more rapidly.
As might be expected, patients 60 years of age and older are most likely to be treated with oral agents. A nearly equal likelihood of oral hypoglycemic agent treatment is found in diabetic patients aged 40 to 59 years. The use of specific sulfonylurea drugs has changed with the introduction of the second-generation agents glipizide and glyburide, which in 1986 accounted for 41% of the market share, leading to a reduced use of chlorpropamide and tolbutamide.
The data tell us nothing about what goes into the decision to treat a patient with an oral hypoglycemic agent or what dictates which sulfonylurea drug is prescribed. Is the decreased use of chlorpropamide and the increased use of second-generation agents the result of marketing strategies or a reflection of physician recognition of differences in drug actions and side effects (2, 11) ? Is the decision to use oral hypoglycemic agents rather than insulin dictated by differences in the goals of therapy, convenience to patients and doctors, or the conviction that oral hypoglycemic agents are more effective or safer than insulin in many patients with NIDDM (12-14)? Do physicians obtain their judgments about therapy from peer-reviewed scientific publications, mass media, or marketing strategies formulated by the pharmaceutical industry?
It is increasingly easier to define trends in therapy of
